AIM: To compare the efficacies of subconjunctival bevacizumab, ranibizumab, and pegaptanib sodium injections for the inhibition of corneal neovascularization in an experimental rat model. METHODS: Sixteen corneas of 1...AIM: To compare the efficacies of subconjunctival bevacizumab, ranibizumab, and pegaptanib sodium injections for the inhibition of corneal neovascularization in an experimental rat model. METHODS: Sixteen corneas of 16 rats were chemically cauterized and randomized into four groups: bevacizumab group that treated with 0.05mL/1.25mg bevacizumab, ranibizumab group that treated with 0.05mL/0.5mg ranibizumab, pegaptanib group that treated with 0.05mL/0.15mg pegaptanib sodium, and control group that treated with 0.05mL saline solution. Digital photographs of the corneas were taken and analyzed using an image analysis software program. All corneas were excised and examined histologically on the 15 th day. RESULTS: Each treatment group had significantly less neovascularized corneal areas and fewer blood vessels than the control group (all P 【0.05). In addition, bevacizumab group had significantly less neovascu-larized corneal areas and fewer blood vessels than ranibizumab and pegaptanib groups (both P 【0.05). However, there was no significant difference between the ranibizumab and pegaptanib groups regarding percentage of neovascularized corneal areas and number of blood vessels (both P 】0.05). CONCLUSION: Subconjunctival bevacizumab, ranibiz-umab, and pegaptanib sodium were effective with no corneal epitheliopathy for inhibiting corneal neovascularization after corneal burn in rats .Bevacizumab was more effective than ranibizumab and pegaptanib sodium.展开更多
目的探讨不同方式丝裂霉素C(MMC)的应用联合手术治疗复发性翼状胬肉的疗效和安全性。方法将44例患者49眼随机分成A、B两组,A组25眼采用术前1月结膜下注射0.1 ml MMC(0.02%)联合翼状胬肉单纯切除术,B组24眼采用翼状胬肉切除+MMC(0.02%)+...目的探讨不同方式丝裂霉素C(MMC)的应用联合手术治疗复发性翼状胬肉的疗效和安全性。方法将44例患者49眼随机分成A、B两组,A组25眼采用术前1月结膜下注射0.1 ml MMC(0.02%)联合翼状胬肉单纯切除术,B组24眼采用翼状胬肉切除+MMC(0.02%)+角膜缘干细胞移植术,术后随访12个月。结果 A组复发3眼,复发率12.0%,B组复发4眼,复发率16.7%,2组差异无统计学意义(P>0.05)。A组1眼出现胬肉切除区巩膜无血管化,B组2眼发生持续性角膜上皮缺损,2组差异无统计学意义(P>0.05)。结论 2种方法治疗复发性翼状胬肉均安全有效,但术前1月结膜下注射0.1 ml MMC(0.02%)联合翼状胬肉单纯切除术具有操作简单、手术时间短和结膜组织损伤少等优点,值得临床推广应用。展开更多
文摘AIM: To compare the efficacies of subconjunctival bevacizumab, ranibizumab, and pegaptanib sodium injections for the inhibition of corneal neovascularization in an experimental rat model. METHODS: Sixteen corneas of 16 rats were chemically cauterized and randomized into four groups: bevacizumab group that treated with 0.05mL/1.25mg bevacizumab, ranibizumab group that treated with 0.05mL/0.5mg ranibizumab, pegaptanib group that treated with 0.05mL/0.15mg pegaptanib sodium, and control group that treated with 0.05mL saline solution. Digital photographs of the corneas were taken and analyzed using an image analysis software program. All corneas were excised and examined histologically on the 15 th day. RESULTS: Each treatment group had significantly less neovascularized corneal areas and fewer blood vessels than the control group (all P 【0.05). In addition, bevacizumab group had significantly less neovascu-larized corneal areas and fewer blood vessels than ranibizumab and pegaptanib groups (both P 【0.05). However, there was no significant difference between the ranibizumab and pegaptanib groups regarding percentage of neovascularized corneal areas and number of blood vessels (both P 】0.05). CONCLUSION: Subconjunctival bevacizumab, ranibiz-umab, and pegaptanib sodium were effective with no corneal epitheliopathy for inhibiting corneal neovascularization after corneal burn in rats .Bevacizumab was more effective than ranibizumab and pegaptanib sodium.
文摘目的探讨不同方式丝裂霉素C(MMC)的应用联合手术治疗复发性翼状胬肉的疗效和安全性。方法将44例患者49眼随机分成A、B两组,A组25眼采用术前1月结膜下注射0.1 ml MMC(0.02%)联合翼状胬肉单纯切除术,B组24眼采用翼状胬肉切除+MMC(0.02%)+角膜缘干细胞移植术,术后随访12个月。结果 A组复发3眼,复发率12.0%,B组复发4眼,复发率16.7%,2组差异无统计学意义(P>0.05)。A组1眼出现胬肉切除区巩膜无血管化,B组2眼发生持续性角膜上皮缺损,2组差异无统计学意义(P>0.05)。结论 2种方法治疗复发性翼状胬肉均安全有效,但术前1月结膜下注射0.1 ml MMC(0.02%)联合翼状胬肉单纯切除术具有操作简单、手术时间短和结膜组织损伤少等优点,值得临床推广应用。
